| ALGN |
Report |
Clear Aligner Volume (Q2 2026) |
BEAT |
pred ~695K vs. cons 683K |
MEDIUM |
| ALGN |
Report |
Non-GAAP Operating Margin (Q2 2026) |
BEAT |
pred ~22.0% vs. cons ~21.5% |
MEDIUM |
| ALGN |
Report |
Total Revenue (Q2 2026) |
IN-LINE |
pred ~$1,060M vs. cons $1,051M |
MEDIUM |
| ALGN |
Guide |
Revenue (Q3 2026) |
LOWER |
guide ~$1,025M mid vs. cons-implied ~$1,040M |
MEDIUM |
| ALGN |
Guide |
Revenue (FY 2026) |
UNCHANGED |
reaffirm ~$4,176M mid vs. cons $4,180M |
HIGH |
| ALGN |
Guide |
Non-GAAP Op Margin (FY 2026) |
UNCHANGED |
reaffirm ~23.7% vs. cons ~23.7% |
HIGH |
| ALGN |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| ALGN |
Return |
5-day cumulative residual |
-4.5% (FADE) |
FADE — Q3 guide cut pulls near-term estimates down post-print; sell-side models off next-Q; short-cover bid limits but does not reverse the drift |
MEDIUM |